Hyaluronic Acid Treatment of Facial Fat Atrophy in HIV-positive Patients

H Bugge; A Negaard; L Skeie; B Bergersen


HIV Medicine. 2007;8(8):475-482. 

In This Article


This is the first study using Restylane SubQ to treat HIV-related facial lipoatrophy, and our results show that hyaluronic acid can produce significant improvements in the restoration of facial fat thickness. It was effective in achieving aesthetic correction of the cheeks and provided durable improvement for most patients for at least 1 year. Although some patients had palpable lumps following treatment, there were no serious adverse effects and no treatment interruptions because of side effects. A hyaluronic acid product with larger particles appears to be a useful supplement to fillers for HIV-infected patients in need of treatment for facial lipoatrophy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: